ArticleBlood cancer journal2025

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Nico Gagelmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.